Stay current with the latest press releases from within the industry.
Release issued 9th October 2003
(Fort Worth, TX, USA) — HEALTHPOINT, Ltd., a Texas- based market leader in tissue management, dermatology, and surgical products, has signed a distribution agreement with Mexico City-based Medical Recovery to market COOK Biotech Incorporated's patented wound matrix product, OASIS, in Mexico.
Based on COOK's breakthrough Small Intestinal Submucosa, or SIS Technology, OASIS is a natural, extracellular matrix used to manage a variety of wounds by providing an environment that allows the body to heal itself.
HEALTHPOINT Ltd. signed an exclusive, worldwide agreement with COOK Biotech early last year. HEALTHPOINT initially marketed OASIS in the U.S. and extended marketing efforts to Canada late last year. Discussions for marketing of OASIS in other international markets are currently in process.
"Medical Recovery is very pleased to be HEALTHPOINT's partner in Mexico," said Jorge Crosswell-Martinez, CEO, Medical Recovery. "We believe there is significant market potential for innovative extracellular wound matrix products, which will revolutionize the management of wounds in the national market."
This is HEALTHPOINT's first distribution agreement in Mexico. "This agreement establishes a firm foundation for HEALTHPOINT to extend its patented wound matrix technology and products while providing a platform for future growth in Mexico," said Jay Nisbet, Senior Director of International Business Development for HEALTHPOINT. Benjamin Vicuña, Director of International Business Development, will work with Mr. Nisbet to explore growth opportunities.
Indiana-based COOK Biotech, a leading manufacturer of tissue-engineered biomaterials for numerous medical and surgical applications, will continue to manufacture the product.
"OASIS is an intact, organic, biologically derived matrix that is readily accepted by the body's immunologic system without the rejection sometimes demonstrated by other reconstituted collagen dressings," explains Dwayne Dixon, marketing director for the wound preparation and healing division.
OASIS can be used in the management of partial and full- thickness skin loss injuries, such as pressure, venous, and chronic vascular ulcers, diabetic ulcers, surgical and trauma wounds, second degree burns, abrasions, and autograft donor sites.
The SIS Technology, on which OASIS is based, is a new biomaterial that provides a supportive environment to allow a patient's body to rebuild and repair damaged tissue.
Since its inception in 1992, HEALTHPOINT Ltd., a DFB Pharmaceuticals, Inc. affiliate company, has established a strong domestic US presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for tissue management, dermatology, and surgical.
The company's aggressive research and development efforts have taken unique technologies to the market, setting the pace for a highly trained field sales organization that is expanding across North America and beyond.
DFB, through its affiliate companies, contract partners, and branded marketing organizations, provides technology-driven products, outsourcing services and licensing opportunities for the healthcare industry worldwide.
HEALTHPOINT is based in Fort Worth, Texas, with additional offices in Canada. Visit HEALTHPOINT's web site at www.healthpoint.com.
COOK Biotech Incorporated, located in West Lafayette, Indiana, was established in 1995 to research, develop and manufacture products based on extracelular matrix (ECM) Technology. COOK Biotech is actively developing ECM and scaffold-based biomaterials for numerous medical purposes. Medical products utilizing COOK's patented ECM Technology are currently marketed worldwide for use in wound management and surgical repair of soft tissue. Together with a network of medical practitioners, COOK Biotech is identifying the medical needs most compatible with ECM technology and developing products to meet these needs.
If you want to find out more about the company visit DFB Pharmaceuticals, Inc. profile.
(14th January 2004) Magnus Precht Joins DFB Pharmaceuticals's Newly Acquired Phyton Inc. as President: Precht to Lead World's Largest Biotech Production Facility for Breakthrough Plant Cell Fermentation Technology
Clients in focus...